Missouri House Bill HB2159

Missouri 2022 Regular Session

• Introduced: 1/5/22
• Refer: 1/20/22

Caption

Establishes provisions relating to insurance coverage for insulin drugs and epinephrine auto-injectors

Impact

The bill's passage is expected to have significant implications for state healthcare laws, notably in how insurance policies manage coverage for critical prescription drugs. By extending coverage requirements for insulin and epinephrine auto-injectors, health plans will need to align their policies accordingly, which may involve adjusting premium structures or copayment arrangements. This could lead to lower out-of-pocket expenses for patients and improve overall healthcare access.

Summary

House Bill 2159 establishes provisions related to insurance coverage for insulin drugs and epinephrine auto-injectors. The bill aims to ensure that these essential medications are accessible to individuals who need them, particularly those suffering from diabetes or severe allergic reactions. By mandating that insurance providers cover these drugs, the legislation seeks to alleviate the financial burden on patients who rely on these life-saving treatments.

Contention

While supporters of HB2159 advocate the necessity of ensuring fair access to vital medications, there may be concerns from insurance providers regarding the potential increase in operational costs associated with the mandated coverage. Some legislators may argue that imposing such provisions could lead to higher insurance premiums, which may not only affect the providers but ultimately the consumers as well. Thus, the ongoing discussions around the bill highlight a balance between patient protection and the economic ramifications of expanded coverage.